Molecular classification of Crohn's disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells

被引:199
作者
Burczynski, ME
Peterson, RL
Twine, NC
Zuberek, KA
Brodeur, BJ
Casciotti, L
Maganti, V
Reddy, PS
Strahs, A
Immermann, F
Spinelli, W
Schwertschlag, U
Slager, AM
Cotreau, MM
Dorner, AJ
机构
[1] Wyeth Res, Mol Profiling & Biomarker Discovery Biomarker Lab, Collegeville, PA 19426 USA
[2] Wyeth Res, Clin Res & Dev, Collegeville, PA 19426 USA
[3] Wyeth Res, Mol Profiling & Biomarker Discovery, Cambridge, MA USA
[4] Wyeth Res, Inflammat Res, Cambridge, MA USA
[5] Wyeth Res, Bioinformat Client Serv, Cambridge, MA USA
[6] Wyeth Res, Clin Stat, Cambridge, MA USA
[7] Wyeth Res, Translat Res, Cambridge, MA USA
[8] Wyeth Res, Biometr Res, Pearl River, NY USA
关键词
D O I
10.2353/jmoldx.2006.050079
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Ulcerative colitis (UC) and Crohn's disease (CD) are common inflammatory bowel diseases producing intestinal inflammation and tissue damage. Although emerging evidence suggests these diseases are distinct, similar to 10% of patients remain classified as indeterminate inflammatory bowel disease even after invasive colonoscopy intended for diagnosis. A molecular diagnostic assay using a clinically accessible tissue would greatly assist in the classification of these diseases. In the present study we assessed transcriptional profiles in peripheral blood mononuclear cells from 42 healthy individuals, 59 CD patients, and 26 UC patients by hybridization to microarrays interrogating more than 22,000 sequences. Supervised analysis identified a set of 12 genes that distinguished UC and CD patient samples with high accuracy. The alterations in transcript levels observed by microarray were verified by real-time polymerase chain reaction. The results suggest that a peripheral blood mononuclear cell-based gene expression signature can provide a molecular biomarker that can complement the standard diagnosis of UC and CD.
引用
收藏
页码:51 / 61
页数:11
相关论文
共 29 条
[1]  
Barrera S, 1996, J CELL PHYSIOL, V166, P130, DOI 10.1002/(SICI)1097-4652(199601)166:1<130::AID-JCP15>3.0.CO
[2]  
2-J
[3]   How could pathologists improve the initial diagnosis of colitis? Evidence from an international workshop [J].
Bentley, E ;
Jenkins, D ;
Campbell, F ;
Warren, B .
JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (12) :955-960
[4]  
BOURMA G, 2003, NAT REV IMMUNOL, V3, P521
[5]   Platelets in inflammatory bowel disease: Clinical, pathogenic, and therapeutic implications [J].
Danese, S ;
de la Motte, C ;
Fiocchi, C .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (05) :938-945
[6]  
DEBRUIN PAF, 1988, THROMB HAEMOSTASIS, V60, P262
[7]   DISTURBED FIBRINOLYSIS IN PATIENTS WITH INFLAMMATORY BOWEL-DISEASE - A STUDY IN BLOOD-PLASMA, COLON MUCOSA, AND FECES [J].
DEJONG, E ;
PORTE, RJ ;
KNOT, EAR ;
VERHEIJEN, JH ;
DEES, J .
GUT, 1989, 30 (02) :188-194
[8]   Biased JH usage in plasma cell immunoglobulin gene sequences from colonic mucosa in ulcerative colitis but not in Crohn's disease [J].
Dunn-Walters, DK ;
Boursier, L ;
Hackett, M ;
Spencer, J .
GUT, 1999, 44 (03) :382-386
[9]   Ulcerative colitis [J].
Farrell, RJ ;
Peppercorn, MA .
LANCET, 2002, 359 (9303) :331-340
[10]   Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response [J].
Furrie, E ;
Macfarlane, S ;
Cummings, JH ;
Macfarlane, GT .
GUT, 2004, 53 (01) :91-98